Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy

BACKGROUND: Autologous chimeric antigen receptor (CAR) T cell therapy is a promising therapeutic strategy for treating hematologic malignancies. A spectrum of serious complications caused by CAR-T cells has caught great attention. We developed a novel CAR against CD19 namely UWC19, consisting anti-C...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Sheng-I, Ko, Ming-Chin, Dai, Yi-Han, Lin, Hsin-An, Chen, Lih-Chyang, Huang, Kuo-Yang, Pang, Te-Ling, Kuo, Cheng-Yi, Lin, Hsin-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290534/
https://www.ncbi.nlm.nih.gov/pubmed/32566611
http://dx.doi.org/10.21037/atm.2020.02.148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290534/
https://www.ncbi.nlm.nih.gov/pubmed/32566611
http://dx.doi.org/10.21037/atm.2020.02.148

Ejemplares similares